Articles
Results of a dose-escalation/expansion study in the US population among patients with extrapancreatic and pancreatic neuroendocrine tumors (NETs) indicate promising antitumor activity of the multitargeted tyrosine kinase inhibitor surufatinib, with a safety profile consistent with that previously described in the SANET-ep trial.
Subgroup analysis data of the randomized phase 3 SANET-ep trial indicate that the clinical benefits of the multitargeted tyrosine kinase inhibitor surufatinib therapy also extended to major subgroups by Ki67 and primary tumor origin in patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (NETs).
Findings of a retrospective analysis of real-world data indicate that retreatment with 2 extra cycles of peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE provided survival benefit in patients with disease progression after initial PRRT.
Findings of a retrospective analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) indicate that peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE may provide clinical benefit and does not significantly impair health-related quality of life (HRQoL).
Real-world safety data from the US expanded access program of Lu-DOTATATE showed that the safety profile was consistent with that previously described in clinical trials of patients with advanced midgut neuroendocrine tumors (NETs).
Results of a comprehensive genomic profiling study indicate differences in genomic alterations detected from primary tumor, metastatic tumor tissue, and liquid biopsy in patients with intrahepatic CCA; IDH1 and FGFR2 genomic alterations are detectable in liquid biopsy, with potential practice-changing implications in clinical practice.
The ongoing PROOF trial (NCT03773302) is evaluating the efficacy and safety of infigratinib versus gemcitabine plus cisplatin as frontline therapy in patients with advanced CCA harboring FGFR2 gene rearrangements.
Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.
Genomic data analysis of publicly available data supports the high prevalence of potentially actionable mutations in patients with CCA, supporting use of personalized therapies alone or in combination with chemotherapy.
Post-hoc analysis of the phase 2 FIGHT-202 study showed that second-line pemigatinib treatment resulted in a numerically longer PFS than standard systemic second-line treatment in patients with previously treated advanced/metastatic CCA.